English | 繁體

Search in the results

UM

Browse/Search Results:  1-2 of 2 Help

Selected(0)Clear Items/Page:    Sort:
Cost-effectiveness of camrelizumab plus rivoceranib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma Journal article
Zou, Huimin, Lai, Yunfeng, Chen, Xianwen, Ung, Carolina Oi Lam, Hu, Hao. Cost-effectiveness of camrelizumab plus rivoceranib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma[J]. Therapeutic Advances in Gastroenterology, 2025, 18, 1-13.
Authors:  Zou, Huimin;  Lai, Yunfeng;  Chen, Xianwen;  Ung, Carolina Oi Lam;  Hu, Hao
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:3.9/4.0 | Submit date：2025/01/22
Camrelizumab  Cost-effectiveness Analysis  Hepatocellular Carcinoma  Partitioned Survival Model  Rivoceranib  
Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis Journal article
Liu, Xiaoyan, Lang, Yitian, Chai, Qingqing, Lin, Yan, Liao, Yahui, Zhu, Yizhun. Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis[J]. Frontiers in Pharmacology, 2022, 13.
Authors:  Liu, Xiaoyan;  Lang, Yitian;  Chai, Qingqing;  Lin, Yan;  Liao, Yahui; et al.
Favorite | TC[WOS]:4 TC[Scopus]:4  IF:4.4/5.0 | Submit date：2023/01/30
Atezolizumab  Cost-effectiveness  Metastatic Urothelial Cancer  Partitioned Survival Model  The Perspective Of The United States And China